Man Group’s BioXcel Therapeutics BTAI Stock Holding History

Man Group’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$129K	Buy	96,473 +39,648	+70%	+$65.3K	﹤0.01%	2339
2025 Q4	$90.9K	Buy	+56,825	New	+$117K	﹤0.01%	2207

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's BTAI Position: Q1 2026 in Review

Man Group increased its BioXcel Therapeutics (BTAI) stake by 70% in Q1 2026, buying an estimated $65.3K and bringing the position to 96,473 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Man Group first reported a position in BTAI in Q4 2025 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Man Group held 96,473 shares of BioXcel Therapeutics worth $129K as of Q1 2026.
Man Group bought 39,648 BioXcel Therapeutics shares in Q1 2026, an estimated $65.3K.
BioXcel Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2339 holding.
Man Group first reported a position in BioXcel Therapeutics in Q4 2025 and has held it in 2 quarters since.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.